Results 221 to 230 of about 1,871,257 (334)

Usefulness of low-molecular-weight heparin in hemodialysis patients with heparin-induced immune thrombocytopenia

, 1989
Michihiko Suzuki, A Soezima, Shigeru Motohashi, Yasushi Kamiya, Yasuyuki Uechi, Kimimasa Nakabayashi, Kiyoshi Kitamoto, Toshihiko Nagasawa, Tuneo Kimura   +8 more
openalex   +2 more sources

Serologically documented loracarbef (Lorabid)-induced immune thrombocytopenia [PDF]

, 2003
Omar S. Aljitawi, K. Kathiravan, Brian R. Curtis, Daniel W. Bougie, Richard H. Aster   +4 more
openalex   +1 more source

Combination of fixed low‐dose nivolumab and bendamustine in children with high‐risk relapsed/refractory classical Hodgkin lymphoma

British Journal of Haematology, EarlyView.
A retrospective study of 18 pediatric patients with high‐risk relapsed/refractory classical Hodgkin lymphoma demonstrated that a fixed low‐dose combination of nivolumab and bendamustine achieved an 88% complete response rate, with 1‐year progression‐free survival (PFS) of 88.2% and overall survival (OS) of 94.4%.
Shyam Srinivasan, Aditya Narayan, Chetan Dhamne, Akanksha Chichra, Poonam Khemani, Nidhi Dhariwal, Raghwesh Ranjan, Sneha Shah, Tanuja Shet, Venkata Rama Mohan Gollamudi, Nirmalya Roy Moulik, Shripad D. Banavali, Gaurav Narula   +12 more
wiley   +1 more source

Anti‐thymocyte globulin in immune‐mediated cytopenias: A monocentric experience and literature review

British Journal of Haematology, EarlyView.
Anti‐thymocyte globulin in multi‐refractory immune‐mediated cytopenia is an effective treatment, with response rate as high as 65%. Younger patients, presenting with thrombocytopenia or neutropenia, and those with LGL and STAT3 mutations appear to be more likely responsive.
Luca Guarnera, Arooj Ahmed, Carlos Bravo‐Perez, Olisaemeka D. Ogbue, Matteo D'Addona, Zachary Brady, Serhan Unlu, Christopher Haddad, Aashray Mandala, Arda Durmaz, Carmelo Gurnari, Valeria Visconte, Jaroslaw P. Maciejewski   +12 more
wiley   +1 more source

Preoperative detection and management of immune heparin-induced thrombocytopenia in patients undergoing heart surgery with iloprost [PDF]

, 2004
George M. Palatianos, Christophoros N. Foroulis, Maria I Vassili, Phaedra Matsouka, George Astras, George H. Kantidakis, Eugenia Iliopoulou, E Melissari   +7 more
openalex   +1 more source

Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination

The Lancet, 2021
A. Bayas, Martina Menacher, M. Christ, L. Behrens, A. Rank, M. Naumann   +5 more
semanticscholar   +1 more source

Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK: A 20‐year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT)

British Journal of Haematology, EarlyView.
We report the UK experience of autologous haematopoietic stem cell transplantation (AHSCT) for multiple sclerosis (MS) in 364 patients. In our observational study, transplant‐related mortality was 1.4%, Epstein–Barr virus reactivation occurred in 75.9%, while disability progression‐free survival was 83.5% at 2 years post‐AHSCT and 62.4% at 5 years.
Majid Kazmi, Paolo A. Muraro, Varun Mehra, Ian Gabriel, Eleonora De Matteis, Gavin Brittain, Alice Mariottini, Richard Nicholas, Eli Silber, Julia Lee, Rachel Pearce, Ruth Paul, Maria Pia Sormani, Alessio Signori, Victoria Potter, Eduardo Olavarria, Ram Malladi, Basil Sharrack, John A. Snowden   +18 more
wiley   +1 more source

Immune-mediated thrombocytopenia secondary to suramin

, 1993
Andrew D. Seidman, Michael Schwartz, Lillian Reich, Howard I. Scher   +3 more
openalex   +1 more source

Immune thrombocytopenia in a 22‐year‐old post Covid‐19 vaccine

American journal of hematology/oncology, 2021
O. H. Tarawneh, Husam S Tarawneh
semanticscholar   +1 more source

Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies

British Journal of Haematology, EarlyView.
A retrospective analysis of patients with chronic myelomonocytic leukaemia treated with oral decitabine 35 mg + cedazuridine 100 mg suggested favourable outcomes, particularly in higher risk patients. The results provide a rationale for further prospective study of oral decitabine/cedazuridine to identify subgroups of this population who would benefit ...
Michael R. Savona, Olatoyosi Odenike, Gail J. Roboz, Harshad Amin, Amy E. DeZern, Elizabeth A. Griffiths, Kim‐Hien Dao, Amer M. Zeidan, Bhavana Bhatnagar, Rena Buckstein, Brian Leber, Mary‐Margaret Keating, Somedeb Ball, Aram Oganesian, Yuri Sano, Harold N. Keer, Guillermo Garcia‐Manero   +16 more
wiley   +1 more source